Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus Life Sciences (Nasdaq: TLSI) announced that CEO and President Mary Szela and CFO David Patience will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. They will hold one-on-one investor meetings on September 14–15 and a Fireside chat on September 14 at 5:00 p.m. ET.
A webcast replay of the Fireside chat will be available for 90 days in the Events section of the TriSalus investor website. TriSalus develops oncology-focused medical technology, including its Pressure-Enabled Drug Delivery (PEDD) devices and nelitolimod, an investigational immunotherapy for solid tumors in the liver and pancreas.
TriSalus Life Sciences (Nasdaq: TLSI) reported second quarter 2026 revenue of $11.4 million from TriNav system sales, up 1.7% year over year. Gross margin rose to 86.8% from 83.9%, primarily due to lower cost per TriNav unit. Operating loss widened to $9.8 million versus $7.3 million, and net loss attributable to common stockholders was $9.2 million, with basic and diluted loss per share of $0.16 compared to $0.27 in 2025.
Adjusted EBITDA loss was $7.1 million, versus $5.3 million a year earlier. Cash and cash equivalents totaled $46.3 million at June 30, 2026, supported by $46.0 million in gross equity offering proceeds in Q1. The company maintained full-year 2026 revenue guidance of $54–$57 million, implying 19–26% growth over 2025, and highlighted a new CMS G-code extending reimbursement for certain vascular embolization procedures using pressure-generating catheters.
TriSalus Life Sciences (Nasdaq: TLSI) announced that CEO and President Mary Szela and CFO David Patience will participate in the Canaccord Genuity 46th Annual Growth Conference. They will hold one-on-one investor meetings on August 11–12 and join a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. A webcast replay of the corporate overview will be accessible for 90 days in the Events section of the company’s investor website.
TriSalus is an oncology-focused medical technology company whose platform combines Pressure-Enabled Drug Delivery (PEDD) devices with the investigational immunotherapy nelitolimod. Two FDA-cleared devices, TriNav for liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors, use PEDD to deliver therapeutics. The company is in the final stages of data completion for several phase 1 trials of nelitolimod and plans to explore development partnerships.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss its financial results for the quarter ended June 30, 2026. A detailed earnings press release will be issued before the call, and live access plus a replay will be available via the company’s investor relations website, with phone participation requiring prior online registration for dial-in details and PIN.
Summary not available.
TriSalus Life Sciences (Nasdaq: TLSI) reported Q1 2026 revenue of $8.9 million, down 2.9% year over year, with gross margin improving to 86.2%. Operating loss was $8.4 million, while net income to common stockholders reached $1.5 million, driven by non-cash derivative gains.
The company raised $46 million, ending the quarter with $56.6 million in cash, and revised 2026 revenue guidance to $54–$57 million. TriSalus reported clinical and real-world data supporting its PEDD platform and progressed commercial expansion for the TriNav system.
TriSalus Life Sciences (Nasdaq: TLSI) reported real-world data on its Pressure-Enabled Drug Delivery (PEDD) technology in TACE and TARE procedures for liver cancers. In 603 PEDD vs. 16,210 non-PEDD patients, PEDD was associated with fewer complications, reduced 30-day hospitalizations, and about $7,734 per-patient charge avoidance.
Benefits included lower fatigue and lymphopenia rates, especially at high-volume PEDD centers, and higher delivered doxorubicin doses with fewer side effects, suggesting improved targeting and preserved immune function.
TriSalus Life Sciences (Nasdaq: TLSI) initiated patient enrollment for the PREDICTT trial on May 4, 2026, an investigator-led prospective study at UT MD Anderson assessing its TriNav Infusion System and Pressure-Enabled Drug Delivery (PEDD) with Y90 radioembolization in liver tumors.
The single-arm study will enroll approximately 20 adults with unresectable primary or metastatic liver tumors to measure CT-based tumor-to-normal liver ratios, correlate imaging with tumor dose and microsphere distribution, and evaluate safety.
TriSalus Life Sciences (Nasdaq: TLSI) will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss first quarter 2026 financial results for the quarter ended March 31, 2026. A press release with results will be issued before the call.
Dial-in registration is required; webcast and replay will be available on the company investor relations website.
TriSalus Life Sciences (Nasdaq: TLSI) will present new clinical and preclinical data at the SIR 2026 Annual Scientific Meeting April 11–15, 2026 in Toronto. Presentations on April 13–14 showcase the Pressure Enabled Drug Delivery™ (PEDD™) platform across liver, pancreatic and uterine applications.
The company highlighted investigator and preclinical work and noted nearing completion of multiple Phase 1 data sets and upcoming partnership discussions.